SAN DIEGO, November 14, 2022 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the spine technology innovation leader focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, has announced today that it will continue its partnership with the Cervical Spine Research Society (CSRS) as a Diamond Sponsor and participate in CSRS 50e Annual meeting held November 16 to 19 in San Diego.
“The recent launch of our leading posterior cervical fusion solution, Reline Cervical, and our sponsorship of the annual meeting of a preeminent cervical society, CSRS, underscores our shared belief in advancing cervical technology,” said Chris Barry, CEO of NuVasive. “We look forward to showcasing our complete and procedurally integrated C360 portfolio, and its first step towards smart surgery with full compatibility with Pulse.”
NuVasive will host two workshops on Thursday, November 17 in the Hillcrest CD room. From 6:30 a.m. to 7:15 a.m. PTa practical workshop, TDR: What are you waiting for? Fantasy versus reality, featuring Dr. Ali MesiwalaDISC Sports and Spine Center and Dr. Rory Murphy, Barrow Neurological Institute. Of 11:30 a.m. to 12:30 p.m. PTan industry lunch-workshop, When approaching cervicothoracic kyphotic deformities – anterior, posterior and 360, featuring Dr. Praveen MummaneniUCSF Health, Dr. Rick SassoIndiana Spine Hospital and Dr. Todd AlbertSpecial Surgery Hospital.
NuVasive Booth #105/204 will showcase the company’s comprehensive C360™ portfolio, comprised of Pulse’s best-in-class access instruments, implants, biomaterials and enabling technologies® for the anterior and posterior cervical spine.
NuVasiveInc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care and change lives. The company’s less invasive and procedurally integrated surgical solutions are designed to provide reproducible, clinically proven results. The Company’s comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, implant systems with magnetic adjustment for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With over $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if not materialized or prove to be incorrect, could cause NuVasive results to differ. materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that contribute to the uncertain nature of these statements include, among others, the risks associated with the acceptance of the Company’s surgical products and procedures by spine surgeons and hospitals, the development and acceptance of new products or product improvements, clinical and statistical verification of the benefits obtained from the use of NuVasive’s products, the Company’s ability to adequately manage inventory as it continues to introduce new products, its ability to recruit and retain management and key personnel; and other risks and uncertainties described in NuVasive’s press releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive undertakes no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date on which it was made.